RxDoctor Payments DataLook up a doctor →

Ricardo Estape, MD

Gynecologic Oncology · Miami, FLNPI 1427012772

Payments from drug & device makers

$546,960in general payments, 2019–2025

Across 553 payments — averaging $989.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Momentis Surgical Inc.$191K
  • Conmed Corporation$132K
  • Intuitive Surgical$90K
  • GSK$46K
  • Pfizer$45K
  • Johnson & Johnson$18K
  • plus $24K from 26 others
$40,000in research payments, 2019–2025

Across 1 payment — averaging $40,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • New Wave Endo-surgical Corp.$40K

What the payments were for

  • Royalty or licence$11,3282%
  • Consulting fees$316,34169%
  • Speaking & faculty fees$12,0783%
  • Travel & lodging$41,6429%
  • Food & beverage$17,4384%
  • Education$58,14213%
  • Gifts$780%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$546,960 in reported general payments places this provider in the 85th percentile of 117 gynecologic oncology providers in Florida.

See all gynecologic oncology providers in Florida

Medicare billing

Part B allowed, 2024
$74,299
Medicare patients
107
Services billed
252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib19$348,447
MyrbetriqMirabegron22$10,738
Ibuprofen350$1,369
Tolterodine Tartrate ErTolterodine Tartrate12$994
Estradiol13$800
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen162$588
Clobetasol EmollientClobetasol Propionate/Emoll11$558
Ondansetron OdtOndansetron30$430
Prochlorperazine Maleate21$292
Pantoprazole Sodium28$197
Clobetasol Propionate11$151
Oxybutynin Chloride ErOxybutynin Chloride20$113
Gabapentin15$112
Ciprofloxacin Hcl12$99
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$51

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$490$348,44719 claims
Astellas Pharma US IncMyrbetriq$115$10,73822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 117 gynecologic oncology providers in Florida.

Other gynecologic oncology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →